Bluebird bio is a biotechnology business based in the US. Bluebird bio shares (BLUE) are listed on the NASDAQ and all prices are listed in US Dollars. Bluebird bio employs 323 staff and has a trailing 12-month revenue of around $21.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.92 |
|---|---|
| 52-week range | $0.85 - $5.53 |
| 50-day moving average | $0.96 |
| 200-day moving average | $1.87 |
| Wall St. target price | $3.57 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.63 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.9233 from 2024-07-05
| 1 week (2024-06-28) | -6.19% |
|---|---|
| 1 month (2024-06-07) | 2.02% |
| 3 months (2024-04-05) | -24.93% |
| 6 months (2024-01-05) | -34.98% |
| 1 year (2023-07-07) | -73.00% |
|---|---|
| 2 years (2022-07-07) | -81.61% |
| 3 years (2021-07-07) | 31.12 |
| 5 years (2019-07-05) | 127.83 |
Valuing Bluebird bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bluebird bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bluebird bio's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.32. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bluebird bio's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $21.7 million |
|---|---|
| Gross profit TTM | $-247,244,000 |
| Return on assets TTM | -15.01% |
| Return on equity TTM | -47.81% |
| Profit margin | 0% |
| Book value | $2.08 |
| Market Capitalization | $189.7 million |
TTM: trailing 12 months
We're not expecting Bluebird bio to pay a dividend over the next 12 months.
Bluebird bio's shares were split on a 1544:1000 basis on 4 November 2021. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1544 shares. This wouldn't directly have changed the overall worth of your Bluebird bio shares – just the quantity. However, indirectly, the new 35.2% lower share price could have impacted the market appetite for Bluebird bio shares which in turn could have impacted Bluebird bio's share price.
Over the last 12 months, Bluebird bio's shares have ranged in value from as little as $0.845 up to $5.53. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bluebird bio's is 0.859. This would suggest that Bluebird bio's shares are less volatile than average (for this exchange).
bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc. , and changed its name to bluebird bio, Inc.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
We analyzed a number of bitcoin ETFs to determine which are best to invest in.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Check out our picks of the best ETF brokers for beginners, options trading, micro-investing and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Check out our picks of the best robo-advisors for new and experienced investors alike.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
There are many ways to invest and grow $50K depending on your financial situation, personal needs and goals.